Annual Report and Notice of AGM

4D pharma plc

(the "Company" or "4D")

Annual Report and Notice of AGM

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces that the Annual Report and Accounts for the year to 31 December 2019 (the "Annual Report") and the notice of the Company's Annual General Meeting ("Notice of AGM") have been posted to shareholders.

Electronic copies of both the Annual Report and the Notice of AGM are now available on the Company's website, www.4dpharmaplc.com.

The AGM will be held in at 9 Bond Court, Leeds, LS1 2JZ, at 10 a.m. on Tuesday, 30 June 2020.

As previously announced on 26 May, In light of the current guidance from the UK Government which prevents public gatherings of more than two people, shareholders, advisers and other guests will not be allowed to attend the AGM and anyone seeking to attend the meeting in person will be refused entry. We therefore encourage shareholders to submit any questions they would like to pose to the Board to [email protected] so as to be received no later than 26 June 2020. All emails should be marked "AGM Question" in the subject line, and will require a shareholder number. If the UK Government's guidance changes before the AGM and allows gatherings of more than two people, we will notify you via the Company's website at www.4dpharmaplc.com.

For further information please contact:

4D

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations [email protected]

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

About 4D

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical studies in progress, namely a Phase II clinical study of BLAUTIX® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

Further information is available at the 4D's website, www.4dpharmaplc.com.